Serum biomarkers are becoming increasingly investigated for risk profiling in MS. Researchers at Brigham and Women’s Hospital have found that changes in two of them after treatment is stopped can signal impending disease activity.

Clinicians and clinician-investigators in the Division of Movement Disorders in the Department of Neurology at Brigham and Women’s Hospital are taking various approaches to provide specialty care for patients facing a broad range of diseases that affect movement, including Parkinson’s disease.

Researchers at Brigham and Women’s Hospital developed the Multiple Sclerosis Disease Activity (MSDA) Test, a multiprotein, serum-based biomarker assay for MS diagnosis, and have reported clinical validation of the assay.

Researchers at Brigham and Women’s Hospital believe an implanted intracranial stimulation system could increase both the strength and duration of tumor treating fields (TTF) delivery.

Researchers at Brigham and Women’s Hospital have redefined the nature of soluble Aβ, a key advance pertinent to future drug design for AD.

Closed-loop systems allow for concurrent sampling and modulation of extended thalamic networks. Researchers at Brigham and Women’s Hospital have become the first to capture continuous recordings of seizure activity from multiple thalamic nuclei using a closed-loop neurostimulation system.